Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 9/20 | 0.41 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.36 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24620414 | 0.95 | PDE4A (0.39) | PDE4APDE7ACSNK1A1CLK4 | |
| SCHEMBL26923054 | 0.87 | PDE4A (0.53) | PDE4APDE7ACSNK1A1CLK4CYP1A2 | |
| SCHEMBL24620166 | 0.82 | PDE4A (0.37) | PDE4APDE7ACSNK1A1CLK4 | |
| SCHEMBL29777877 | 0.81 | PIN1 (0.42) | PDE4APDE7A | |
| SCHEMBL26921208 | 0.81 | PIN1 (0.42) | PDE4APDE7A | |
| SCHEMBL24620114 | 0.80 | PDE4A (0.39) | PDE4APDE7ACSNK1A1CLK4 | |
| SCHEMBL29350000 | 0.75 | PIN1 (0.45) | PDE4ACYP1A2 | |
| SCHEMBL24620552 | 0.75 | PIN1 (0.45) | PDE4ACYP1A2 | |
| SCHEMBL28755614 | 0.69 | JAK2 (0.42) | — | |
| SCHEMBL29637024 | 0.69 | JAK2 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240083917-A1 | Polycyclic Kinase Inhibitor | Xuanzhu Biopharmaceutical Co., Ltd. (CN) | 2024-03-14 | — | — | US | disclosed |
| EP-4289853-A1 | POLYCYCLIC KINASE INHIBITOR | Shandong Xuanzhu Pharma Co., Ltd. (CN) | 2023-12-13 | — | — | EP | disclosed |
| CN-116669741-A | Polycyclic kinase inhibitors | 山东轩竹医药科技有限公司 | 2023-08-29 | — | — | CN | disclosed |
| WO-2022148354-A1 | POLYCYCLIC KINASE INHIBITOR | 山东轩竹医药科技有限公司 | 2022-07-14 | — | — | WO | disclosed |
| WO-2022148354-A1 | POLYCYCLIC KINASE INHIBITOR | 山东轩竹医药科技有限公司 | 2022-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083917-A1 | Polycyclic Kinase Inhibitor | PRKDC, DCK, DMPK | PDE4A 645/4885PDE7A 339/4885CSNK1A1 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.